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Abstract
Background: Antiretroviral therapy (ART) has substantially decreased mortality and HIV-related morbidity. However,
other morbidities appear to be more common among PLHIV than in the general population. This study aimed to
estimate the relative risk of renal disease among people living with HIV (PLHIV) compared to the HIV-uninfected
population.
Methods: We conducted a systematic review and meta-analysis of relative risks of renal disease among
populations of PLHIV reported in studies from the peer-reviewed literature. We searched Medline for relevant
journal articles published before September 2010, yielding papers published during or after 2002. We also searched
conference proceedings of the International AIDS Society (IAS) and Conference on Retroviruses and Opportunistic
Infections (CROI) prior to and including 2010. Eligible studies were observational studies reporting renal disease
defined as acute or chronic reduced renal function with glomerular filtration rate less than or equal to 60 ml/min/
1.73 m2 among HIV-positive adults. Pooled relative risks were calculated for various groupings, including class of
ART drugs administered.
Results: The overall relative risk of renal disease was 3.87 (95% CI: 2.85-6.85) among HIV-infected people compared
to HIV-uninfected people. The relative risk of renal disease among people with late-stage HIV infection (AIDS) was
3.32 (1.86-5.93) compared to other PLHIV. The relative risk of renal disease among PLHIV who were receiving
antiretroviral therapy (ART) was 0.54 (0.29-0.99) compared to treatment-naïve PLHIV; the relative risk of renal disease
among PLHIV who were treated with tenofovir was 1.56 (0.83-2.93) compared to PLHIV who were treated with
non-tenofovir therapy. The risk of renal disease was also found to significantly increase with age.
Conclusion: PLHIV are at increased risk of renal disease, with greater risk at later stages of infection and at older
ages. ART prolongs survival and decreases the risk of renal disease. However, less reduction in renal disease risk
occurs for Tenofovir-containing ART than for other regimens.
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Background
Highly active antiretroviral treatment (ART) has reduced
mortality and decreased HIV-related morbidities, such that
people living with HIV (PLHIV) are living longer, healthier
lives [1]. However, PLHIV face other health challenges.
Comorbid conditions are becoming more important in the
health care of PLHIV [1]. Numerous serious morbidities
are more likely to occur among PLHIV than among the
general population. It is important to understand the
incidence rate of these comorbidities among PLHIV, along
with their risk factors, in order to guide clinical care and
planning of health systems.
Chronic kidney disease (CKD) is increasing worldwide
and the ensuing end stage renal disease necessitates trans-
plantation or dialysis, both of which are highly expensive
[1]. There is no consensus on the risk of renal dysfunction
associated with HIV infection and the use of ART, how-
ever, it is believed to be an important condition dispropor-
tionately affecting PLHIV [2-4]. Numerous studies have
investigated the rates of renal disease and its risk factors
for PLHIV. In this study we conduct a systematic review* Correspondence: dwilson@unsw.edu.au1The Kirby Institute, University of New South Wales, Sydney, NSW 2052,
Australia
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and meta-analysis to assess the relative risk of renal dis-
ease among PLHIV.
Methods
Search strategy
We conducted a comprehensive literature search of the
published literature through Medline with the following
key words: ‘HIV or human immunodeficiency virus or
AIDS or acquired immunodeficiency syndrome’ AND
‘renal failure or kidney failure or renal impairment or kid-
ney impairment or renal insufficiency or kidney insuffi-
ciency or renal disease or kidney disease or acute kidney
injury or glomerulonephritis or GN or nephropathy or
proteinuria or nephritic sediment or hematuria or erythro-
cyturia or leukocyturia or glucosuria or tubulotoxic
damage or Fanconi’s syndrome or HIV-AN or HIVAN or
dialysis or hemodialysis or peritoneal dialysis or ESKD or
ESRF or ESKF’ AND ‘relative risk or risk ratio or RR or
odds ratio or OR or hazard ratio or HR or incidence’. We
also searched abstracts from CROI and International
AIDS Society (IAS) conferences during years 2000-2010,
with the same search terms.
Outcome measures
The primary outcome for our analysis was chronic kidney
disease (CKD) defined as estimated glomerular filtration
rate or eGFR < 60 mL/min/1.73 m2 for greater than or
equal to 3 months irrespective of kidney damage [5].
An eGFR less than 60 mL/min/1.73 m2 for less than
3 months refers to acute renal failure (ARF). The ratio-
nale for the inclusion of individuals with eGFR less than
60 mL/min/1.73 m2 without any other evidence of kidney
damage is that at least 50% of normal kidney function
decreases and the prevalence of complications of CKD
begins to increase below this level [6]. In addition, abnor-
mal proteinuria is more likely to occur at this level,
which is an indication of kidney disease [7]. It is noted
here that there are five stages of CKD, which are defined
as stage 1: eGFR > 90 (normal); stage 2: eGFR: 60-89
(mild), stage 3: 30-59 (moderate); stage 4: 15-29 (severe);
and stage 5: eGFR < 15 (kidney failure) [5]. There is a
complex spectrum of renal diseases, such as HIV-asso-
ciated nephropathy (HIVAN), end-stage renal disease
(ESRD), all-cause nephropathy (ACN), acute renal failure
(ARF), chronic kidney disease (CKD), chronic renal fail-
ure (CRF), tubular dysfunction, and renal impairment
(RI), which can be classified within CKD stages 3, 4 and
5 based on the outcome measure in each individual
study. Our review includes stage 3 (moderate kidney
damage) to stage 5 (kidney failure) CKD. We included
any study that reported an incidence rate ratio (IRR),
relative risk (RR), odds ratio (OR) or hazard ratio (HR) of
the renal events among PLHIV.
Selection of studies
Two reviewers independently assessed each potential rele-
vant article for eligibility (FI, JW). Disagreements were
resolved with other authors until a consensus was reached.
We screened the titles and the abstracts of the 4083 arti-
cles, identified by the search phrases, for appropriateness
before retrieval of the full-text. Studies that reported HIV
and/or AIDS and renal disease, and provided estimates of
risk factors were included in the analysis. Studies that did
not report the risk estimates were excluded from further
review. Non-English and review articles were also
excluded from the analysis. The selection process for stu-
dies included in the formal analysis [2-4,7-26], is presented
in Figure 1.
Data extraction
Two reviewers independently extracted data using a stan-
dardized form. The information recorded from each study
were author, study design, study types, study period, publi-
cation year, follow-up period, sample size, renal disease,
eGFR or other measure, comparator groups, reported out-
come, risk estimates, age, sex, race/ethnicity and geo-
graphic location. The details of the data extraction are
listed in Table 1.
Methods for assessing renal function outcomes
The identified studies measured the change in renal func-
tion by various methods: fourteen studies reported mea-
suring eGFR using an MDRD method, two studies using
the CG formula, one used the CKD-EPI formula and six
studies reported renal dysfunction measured by serum
creatinine (see Table 1). Regardless of method, studies
reporting eGFR less than 60 mL/min/1.73 m2 (at least
moderate CKD) were included for further analysis.
Quality assessment of included studies
Two reviewers independently rated the quality of each
study using the Downs and Black checklist [27] The check-
list comprises of 27 criteria, including (10) types of report-
ing, (3) checks of external validity for the generalisability of
study population, (7) assessments of bias, (6) exploration of
confounding and (1) power. Using this checklist, we calcu-
lated an average quality index score of our 23 non-rando-
mized studies to be 14.9, with a range of 11.5 to 19.
Statistical analysis
We performed a series of meta-analyses based on similar
comparator groups among the studies. The risk estimates
extracted from the publications were either from logistic
regression or proportional hazards models with reported
confidence intervals. The extracted estimates were already
adjusted for common risk factors in each individual study,
such as age, sex, race, smoking, diabetes and hypertension.
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The rational to pool relative risks from these two types of
the models was based on the investigation of D’Agostino
et al. [28]. D’Agostino et al. demonstrated the asymptotic
equivalence of estimating relative risks from logistic
regression and proportional hazards models. Along with
the meta-analysis publication by Lollgen et al. [29] that
adopted this approach, we concluded that it is reasonable
to pool relative risks from these two different models. We
calculated the pooled estimates of risks for groups in
which there were at least two individual studies. We per-
formed meta-analyses to estimate the pooled relative risk
of renal disease among PLHIV compared with HIV-unin-
fected people; PLHIV on ART (including different classes
or specific antiretroviral drugs and duration of ART) com-
pared with PLHIV who are treatment-naïve; people with
late-stage HIV (AIDS) compared with other PLHIV; and
the effect of age on renal disease. We applied general var-
iance-based methods that used confidence intervals
around the effect measures, where all effect types were
ratio measures. Outcomes were pooled using the DerSi-
monian-Laired (DSL) random effects model which
accounts for the heterogeneity of the estimates [30]. We
quantified the degree of heterogeneity by the I-squared
statistic, which can be interpreted as the percentage of
total variation across the studies; a value of zero indicates
no observed heterogeneity [31]. Secondary analyses were
conducted using meta-regression and subgroup analysis.
Two-tailed p-values were considered (p < 0.05) for all
statistical tests except for the meta-regression where we
considered p < 0.10 to detect potential heterogeneity
among covariates. Publication bias was assessed using
Egger’s method [32]. The analyses of this review were con-
ducted in STATA (version 10; STATA Corporation, Col-
lege Station, Texas, USA). The methodology and reporting
of this review conforms to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [33,34].
Results
Study selection
The search strategy initially resulted in 4083 articles
from which we identified 361 for detailed review. After
Figure 1 Information flow diagram of the systematic review. a Qualitative synthesis: results of primary studies are summarized but not
statistically combined; b Quantitative synthesis: Statistical methods applied to combine the results of two or more studies c includes conference
proceedings (7).
Islam et al. BMC Public Health 2012, 12:234
http://www.biomedcentral.com/1471-2458/12/234
Page 3 of 15
Table 1 Details of study populations
Study name Study Type
(Cohort name)
Study
period
Age (Mean) of
participants
Sex
(Male
(%))
Primary
outcome
(Disease)
Location Study
size(N)
Race/
ethnicity
(%)
Average
follow up
(years)
Total
Events
Method for eGFR (<
60 ml/min/1.73m2)
Atta, 2006 [8] Cohort 1995-
2004
42.8 58 HIVAN MD, USA 263 96(B) 8.0 36 MDRD
Buskin, 2009
[9]
Cohort 1996-
2003
36.5 HIVAN USA 59705 6.2(W) 3.5 5042 MDRD
11.5(B)
7.3(H/L)
6.5(A/PI)
9.7(NA/
AN)
4.7(O)
Campbell,
2009 [10]
cross-sectional 1998-
2005
– CKD BT, UK 3439 NR – 81 MDRD
Crane, 2007
[4]
Cohort(UWHIV) 2001-
2006
41 83 Kidney
dysfunction
WA, USA 445 61(W) – 51 CG
23(AA)
16(O)
Crum-
Cianflone,
2010 [11]
cross-sectional 2004-
2005
41 92 Kidney
dysfunction
CA, MD, USA 717 48.7 (C) – 22 MDRD
37.9(AA)
13.4 (O)
Deti, 2010 [7] Cohort(ANRS
CO3)
2004-
2008
43 75 CRF France 2613 NR 3.4 MDRD
Franceschini,
2006 [12]
Cohort 2000-
2002
40 69 ARF NC, USA 705 66(AA) 3.0 serum creatinine
Franey, 2009
[13]
Cohort 2004-
2007
36 31.2 RI South Africa 2189 NR – 287 MDRD
Ganesan,
2010 [14]
Cohort (P) 1986-
2008
29 92 CKD USA 4044 45(AA) 6.5 90 MDRD
44(EA)
Heffelfinger,
2006 [15]
Cohort 2000-
2003
– – RI USA 11362 NR 724 serum creatinine
Horberg, 2010
[3]
Cohort(KP) 2002-
2005
43 86.1 Tubular
dysfunction
CA, ML, VA,
USA
1647 24.5(B) 2.0 MDRD
Ibrahim, 2010
[2]
Cohort(KCH) 1999-
2008
37 62 ARF SL, UK 2556 55.4(B) – 184 MDRD
44.6(W/O)
Jacobson,
2007 [16]
Cohort(MACS) Proteinuria USA 1203 (B) 120
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Table 1 Details of study populations (Continued)
Jones, 2004
[17]
Cohort(CWS) Renal
dysfunction
UK 4183 NR 1175 serum creatinine > 120
Krawczyk,
2004 [18]
Cohort(HOPS) 1992-
2002
43 82.5 CRF GA, USA 6361 43.8(W/
NH)
108 –
5.0(H)
48.8(B)
2.5(O)
Longenecker,
2009 [19]
Cohort(P) 2004-
2007
41 68 CKD CA, USA 554 42(AA) 5.0 CKD-EPI
48(W)
10(O)
Lucas, 2007
[20]
Cohort(ALIVE/
JHHC)
1988-
2005
37 68 ESRD/RRT MD, USA 6255 (AA) 5.7 221 MDRD
Mocroft, 2010
[21]
Cohort
(EuroSIDA)
2004-
2008
43 75.1 CKD Europe,
Israel,
Argentina
85.5(W) 3.7 225 CG
Reisler, 2005
[22]
Cohort(MACS) 2003-
2004
– – CKD USA 1470 NR 53 MDRD
Roe, 2008 [23] Cohort (R) 1998-
2005
35.9 64 ARF SEL, UK 2274 64(B) 8.0 130 MDRD
36(NB)
Szczech, 2002
[24]
Cohort(WIHS) 40 – 2059 71.4(B) 671.0 double serum
creatinine
16.7(W)
11.9(H)
0(O)
Vanig, 2008
[25]
Cohort (R) 2006-
2007
– 94 CKD USA 375 NR MDRD
Wei, 2003 [26] Cohort(P) 37.6 93.2 HIVAN NY, USA 44 (AA) 44
Study group1 Study group2
Study
description
Sample
size (n1)
Event1 Incidence(per
1000py)
Study description Sample
size (n2)
Event2 Incidence(per
1000py)
HR/RR/
OR
95% CI
Study name
Atta, 2006 [8] ART – 26 – Treatment naïve – 10 – 0.3 0.09, 0.98
Buskin, 2009
[9]
Indinavir Treatment naïve 1.15 1.02, 1.29
Ritonavir Treatment naïve 0.87 0.77, 0.98
HAART Treatment naïve 0.3 0.27, 0.34
Campbell,
2009 [10]
Age > = 50
years(Indinavir)
– – Age < 50 years – – 4.92 1.31, 18.4
Indinavir/per
year
1.29 1.00,
1.65
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Table 1 Details of study populations (Continued)
Age > = 50
years(Tenofovir)
Age < 50 years 5.42 1.71, 16.8
Crane, 2007
[4]
Age (30-40)
years
Age < 30 years 0.9 0.2, 3.2
Age (40-50)
years
Age < 30 years 2.1 0.6, 7.6
Age > 50 years Age < 30 years 4.4 1.1, 17.2
(NRTI)
Didanosine
(NRTI)lamivudine/emtricitabine 3.1 1.40, 6.80
PI(Amprenavir/
fos-amprenavir)
NNRTI (efavirenz) 3.6 1.00, 12.5
Crum-
Cianflone,
2010 [11]
Age/10 year
increase
1.99 1.22,
3.24
Tenofovir/per
year
1.54 1.10,
2.15
Deti, 2010 [7] Age/10 year
increase
2.2 1.8, 2.6
CD4 < 200 cells/
mm3
CD4 > 500 cells/mm3 4.04 2.3, 7.1
Tenofovir/per
year
1.4 1.1, 1.8
Franceschini,
2006 [12]
CD4 < 200 cells/
mm3
CD4 > = 200 cells/mm3 4.7 2.5, 8.8
Franey, 2009
[13]
CD4 < 100 cells/
mm3
CD4 > 100 cells/mm3 1.4 1.07, 1.82
Age > 40 years Age < 40 years 4.65 3.54, 6.10
Ganesan,
2010 [14]
Age > = 35
years
Age < 35 years 2.6 1.7, 4.0
CD4 < = 200
cells/mm3
CD4 > = 500 cells/mm3 6.8 3.0, 15.5
CD4(201-349)
cells/mm3
CD4 > = 500 cells/mm4 4.3 2.3, 8.1
CD4(350-499)
cells/mm3
CD4 > = 500 cells/mm5 2.4 1.3, 4.6
Heffelfinger,
2006 [15]
Tenofovir Treatment naïve 1.5 1.1, 1.9
Horberg, 2010
[3]
Tenofovir 964 Non-Tenofovir 683 5.23 2.08, 13.1
Ibrahim, 2010
[2]
Age/10 year
increase
1.04 0.87,
1.24
Indinavir Treatment naïve 1.81 0.53, 6.76
Tenofovir Treatment naïve 1.06 0.46, 2.43
Atazanavir Treatment naïve 1.05 0.20, 5.49
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Table 1 Details of study populations (Continued)
CART Treatment naïve 1.11 0.54, 2.30
CD4(201-350)
cells/mm3
CD4 > 350 cells/mm3 1.56 0.97, 2.48
CD4(101-200)
cells/mm3
CD4 > 350 cells/mm3 2.08 1.11, 3.91
CD4(51-100)
cells/mm3
CD4 > 350 cells/mm3 6.38 3.18, 12.78
CD4(0-50) cells/
mm3
CD4 > 350 cells/mm3 10.29 5.11, 20.98
Jacobson,
2007 [16]
HIV 94 Non-HIV 26 5.1 2.9, 8.9
Jones, 2004
[17]
Tenofovir 1058 84 Treatment naïve 0.22 0.07, 0.69
Krawczyk,
2004 [18]
CD4 < 200 cells/
mm3
200-349 cells/mm3 4.3 2.1, 8.7
HAART Treatment naïve 0.5 0.3, 1.0
Longenecker,
2009 [19]
HIV 337 26 Non-HIV 230 2 6.5 1.5, 28.7
Age/10 year
increase
1.34 1.02,
1.77
Lucas, 2007
[20]
AIDS 1902 125 12.7 No AIDS 2607 51 4.7 2.7 1.9, 4.0
Age(30-49.9) Age < 30 years 1.5 0.7, 3.3
Age > = 50
years
Age < 30 years 2 0.8, 4.7
AIDS 1902 Non-HIV 1751 5.1 3.5, 7.6
HIV 2607 Non-HIV 1751 2.3 1.5, 3.5
Mocroft, 2010
[21]
AIDS No AIDS 2.22 1.14, 4.32
Age/10 year
increase
1.54 1.31,
1.80
Tenofovir/per
year
1.16 1.06,
1.25
Indinavir/per
year
1.12 1.06,
1.18
Atazanavir/per
year
1.21 1.09,
1.34
Lopinavir/r per
year
1.08 1.01,
1.16
Reisler, 2005
[22]
HIV 32 Non-HIV 21 2.5 1.4, 4.5
Tenofovir Non-Tenofovir 2 0.8, 4.9
Roe, 2008 [23] CD4 < 100 cells/
mm3
CD4 > 200 cells/mm3 6.75 2.5, 18.3
Islam
et
al.BM
C
Public
H
ealth
2012,12:234
http://w
w
w
.biom
edcentral.com
/1471-2458/12/234
Page
7
of
15
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CD4(100-199)
cells/mm3
CD4 > 200 cells/mm3 3.02 0.99, 9.13
AIDS No AIDS 6.7 3.4, 13.3
Szczech, 2002
[24]
CD4 < = 200
cells/mm3
CD4 > 200 cells/mm3 3.57 1.72, 7.14
Vanig, 2008
[25]
Tenofovir 253 Non-Tenofovir 122 1.83 1.11, 3.02
PI Non-PI 1.27 0.84, 1.91
Wei, 2003 [26] ART Treatment naïve 1.51 0.37, 6.20
CD4 < = 100 s
cell/mm3
CD4 > = 100 cells/mm3 2.73 0.82, 9.14
A, Asian; AA, African-American; B, Black; EA, European American; H, Hispanic; NH, Non-Hispanic; L, Latino; NB, Non-b lack; PI, Pacific Islander; NA, Native American; AN, Alaska Native; W, White; O, Others; MD,
Maryland; NC, North Carolina; WA, Washington; GA, Georgia; SL South London; SEL, Southeast London; BT, Brighton; NR, Not Reported; NA, Not Applicable; Sr, Serum; R, Retrospective; P, Prospective; WIHS, Women’s
Interagency HIV Study; UWHIV, University of Washington HIV; ALIVE, AIDS Link to the Intravenous Experience; JHHC, Johns Hopkins HIV Cohort; KP, Kaiser Permanente; MACS, Multicentre AIDS Cohort Study; CWS,
Chelsea and Westminster; HOPS, HIV Outpatient Study; KCH, Kings College Hospital; ANRS CO3, National agency for AIDS research Aquitaine Cohort; MDRD, Modification of Diet in Renal Disease-an equation to
estimate GFR that incorporates serum creatinine, age, sex and race; CG, Cockcroft-Gault equation to estimate GFR that incorporates serum creatinine, age, sex and weight; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration-an equation that take into account serum creatinine, age, sex and race.
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reviewing the titles and abstracts we excluded 331 stu-
dies that were not relevant to renal disease among
PLHIV. Of 30 articles selected for the potential eligibil-
ity, 14 were excluded as they did not relate to our study
question. We also searched conference proceedings of
Conference on Retroviruses and Opportunistic Infec-
tions (CROI) and International AIDS Society prior to
and including 2010. Out of the initial 451 results from
the conferences, 7 abstracts were selected [7,14-17,
22,25]. A total of 23 studies were included for further
analysis, two of which were cross-sectional studies, one
was a case-control study and twenty were cohort
studies. The studies varied greatly with respect to the
various comparator groups. Details of the search strate-
gies are listed in Figure 1 and the characteristics of the
included studies are presented in Table 1.
Relative risk of renal disease for PLHIV versus HIV-
uninfected people
Three identified studies reported the risk of kidney disease
among PLHIV [16,19,22]. Jacobson et al. reported the rela-
tive risk of kidney disease among 542 HIV-infected men
with abnormal proteinuria, having CKD stages 3-5, to be
5.1 (95%CI: 2.9-8.9), compared to 661 HIV-seronegative
men [16]. This USA-based study recruited adult men and
adjusted estimates by age, race, hypertension and diabetes
[16]. Another USA-based study, conducted by Longe-
necker et al [19], compared 337 HIV-infected people (294
ART-experienced) with 230 control subjects. The esti-
mated relative risk of CKD stage 3 among PLHIV was 6.5
(1.5-28.7). The study populations consisted of both male
and females aged 41 years or older. The relative risk was
adjusted for demographic risk factors such as age, sex and
race. Reisler et al. reported the adjusted relative risk of
CKD stage 4 among 1470 HIV-infected men compared to
HIV-uninfected men to be 2.5 (1.4-4.5) [22]. The pooled
relative risk of kidney disease among PLHIV from our
meta-analysis was found to be 3.87 (2.18-6.85) compared
to HIV-uninfected people (Figure 2a). There was no statis-
tically significant evidence of heterogeneity between the
studies (I-squared 43.8%, p = 0.169).
Effect of antiretroviral treatment
We identified five relevant studies estimating the relative
risk of renal failure associated with antiretroviral therapy
(ART), compared to treatment-naïve HIV-infected peo-
ple. Atta et al. reported that the hazard ratio of CKD
stage 4 associated with exposure to ART, defined as the
initiation of at least one antiretroviral agent, was 0.30
(0.09-0.98). This analysis adjusted for injecting drug
users, hepatitis C, GFR and other treatments such as cor-
ticosteroids; excluding age, all other characteristics were
similar in the two groups [8]. Buskin et al. estimated the
adjusted HR of CKD stage 1 to 5 to be 0.30 (0.27-0.34),
adjusting for all known risk factors [9]. Of note, 1.1% and
2.9% of patients in this study were CKD stage 1 and
2 respectively and 8.2% of patients were CKD unknown.
Ibrahim et al. calculated an adjusted IRR of CKD stage 3
to be 1.11 (0.54-2.30) among HIV-infected people who
were exposed to ART not containing indinavir, tenofovir
or atazanavir compared with untreated PLHIV [2].
Krawczyk et al. estimated the relative risk of CKD (unde-
fined) to be 0.50 (0.30-1.0) where age, sex and ethnicity
were well-matched [18]. Wei et al. estimated the risk
ratio of CKD stage 5 among people exposed to ART ver-
sus treatment-naïve PLHIV to be 1.51 (0.37-6.2) [26]. We
estimated the pooled relative risk across all studies to be
0.54 (0.29-0.99) for renal disease among PLHIV who
received ART compared to treatment-naïve PLHIV
(Figure 2b). The heterogeneity across these studies was
measured to be I-squared = 80.5% (p < 0.001).
Relative risk of renal disease for tenofovir-based
treatment
Some studies have singled out ART containing the antire-
troviral drug, tenofovir (TDF), as being an important factor
for the incidence of CKD. We collated data from available
studies and compared the relative risk of CKD for HIV-
infected people treated with TDF-based ART with HIV-
infected people receiving non-TDF-based ART. Four
cohort studies and one case-control study were relevant for
inclusion in this analysis. Horberg et al. reported that the
relative risk of CKD stage 3 for people on TDF-based ART
was 5.23 (2.08-13.1) compared to people on ART not con-
taining TDF [3]. Reisler et al. reported that the relative risk
of CKD stage 3 to 5 using TDF was 2.00 (0.8-4.9) compared
to non-TDF-based drugs [22]. Vanig et al. found a relative
risk of CKD stage 3 for people receiving TDF-based ART
to be 1.83 (1.11-3.02) and Heffelfinger et al. estimated an
adjusted odds ratio of CKD stage 3 attributable to TDF of
1.5 (1.1-1.9) [15]. Finally, a case-control study reported by
Jones et al. estimated the rate ratio between TDF-contain-
ing and non-TDF-based ART to be 0.22 (0.07-0.69) [17].
Pooling the five estimates, we calculated that the overall
relative risk of CKD was 1.56 (0.83-2.93) for people on
TDF-based ART compared to non-TDF-based ART (Figure
2c). The heterogeneity across these studies was estimated as
I-squared = 78.4%, p = 0.001.
The effect of treatment duration
We investigated whether the duration of exposure to ART
influences the risk of CKD. We were able to combine the
estimates of three relevant studies [7,11,21]. The combined
relative risk of CKD among PLHIV with exposure to TDF-
based ART was found to be 1.29 (1.08-1.54) per year of
treatment (Figure 2d). There was no strong evidence of
heterogeneity between the studies (I-squared = 52.5%, p =
0.122).
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Figure 2 Forest plot of studies and pooled estimate of relative risk of renal disease. In (a) HIV-infected versus HIV-uninfected people; (b)
HIV-infected people exposed to antiretroviral treatment versus treatment-naïve PLHIV; (c) HIV-infected people exposed to tenofovir-based ART
versus non-tenofovir-based ART; (d) HIV-infected people per year of exposure to TDF-based ART. (e)Relative risk of renal disease in PLHIV
according to CD4 count. Mid-values of the range of reported CD4 categories are plotted; each point/bar presents data from a single study,
illustrating the RR/95% CI of CKD < 60 for the low CD4 group (CD4 value shown on the abscissa) compared to the high CD4 group (presented
in Table 3). (f)Forest plot of studies and pooled estimate of relative risk of renal disease among people in AIDS stage versus non-AIDS HIV
infection. (g)Relative risk of renal disease in HIV-infected people in various age groups (presented in Table 2). 1Crane, 2007; compared with < 30,
2Lucas, 2007; compared with < 30, 3Ganesan, 2010; compared with < 35 4Franey, 2009; compared with < 30; 5Lucas, 2007; compared with < 50;
6Campbell, 2009; compared with < 50. (h)Forest plot of studies and pooled estimate of relative risk of renal disease in HIV-infected people by
10-year increment in age.
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Relative risk of CKD with CD4 ± T-cell-count
Nine studies identified in our review reported that CD4
cell count was associated with the risk of CKD among
PLHIV [2,7,12-14,18,23,24,26] (see Table 3). We were
unable to combine the estimates in a meta-analysis due to
differences in comparator groups (see Table 3 for details
of CD4 count categories in all studies). Deti et al. esti-
mated the relative risk of CKD stage 3 among HIV-
infected people with CD4 count less than 200 cells/mm3
and between 200-500 cells/mm3 to be 4.04 (2.3-7.1) and
1.3 (0.81-2.2), respectively, compared with those with CD4
count greater than 500 cells/mm3 [7]. Franceschini et al.
reported the relative risk of CKD stage 3 for HIV-infected
people with CD4 count less than 200 cells/mm3 to be 4.70
(2.5-8.8) compared with those with CD4 count greater
than or equal to 200 cells/mm3[12]. Franey estimated this
risk to be 1.4 (1.1-1.8) with CD4 count less than 100 cells/
mm3compared to > 100 cells/mm3 [13]. A cohort study
reported by Ganesan et al. compared the risk of CKD
stage 3 for different CD4 count categories [14]. They
found that the relative risks of CKD for HIV-infected peo-
ple with CD4 count less than or equal to 200 cells/mm3,
between 201-349 cells/mm3 and between 350-499 cells/
mm3 were 6.8 (3.0-15.5), 4.3 (2.3-8.1) and 2.4 (1.3-4.6)
compared with people with a CD4 count greater than or
equal to 500 cells/mm3, respectively. Overall, we found a
negative correlation between CD4 count and renal disease
(Figure 2e) with lower CD4 counts associated with greater
risk of renal disease (correlation, r = -0.52). Other cohort
studies support this conclusion, after adjusting for other
major confounders [2,18,23,24,26].
Relative risk of kidney disease for late-stage HIV versus
non-AIDS
We estimated the relative risk of renal disease among
people in late-stage HIV infection (AIDS) compared to
other PLHIV. We identified three studies [20,21,23] esti-
mating relative risk of kidney disease among people who
have AIDS symptoms compared to other PLHIV. Lucas
et al. reported the incidence rate ratio of end-stage kid-
ney disease (ESKD), defined as receiving renal replace-
ment therapy for 51 HIV-infected people without AIDS
compared with 125 people with AIDS to be 2.7 (1.9-4.0)
[20]. The IRR was adjusted by age, sex, AIDS status and
HIV treatment era. Another study, by Mocroft et al. [21]
estimated the relative hazard of chronic kidney disease
having eGFR ≤ 60 ml/min per 1.73 m2 for ≥ 3 months
among 6843 HIV-positive people to be 2.22 (1.14-4.32)
after adjusting for age, sex, diabetes, hypertension and
other risk factors. Roe et al. [23] estimated the relative
risk of CKD stage 3 among 2274 HIV-infected people to
be 6.72 (3.4-13.3), adjusting for major confounding fac-
tors. We note that this study classified the episodes of
ARF into two onsets of action after initiating HIV care;
we included the estimate of early onset of CKD stage 3 to
avoid confounding with other co-infections in the late-
onset of CKD. The pooled relative risk of CKD among
people with late-stage HIV infection was 3.32 (1.86-5.93)
compared to other PLHIV. There was statistically signifi-
cant evidence of heterogeneity among these studies
(I-squared 69.3%, p = 0.039) (Figure 2f).
Relative risk of renal disease with age
We investigated whether the risk of renal disease depends
on age. We identified five relevant studies that estimated
the relative risk of renal disease for every 10 year incre-
ment in age where the reference group was age-matched
HIV-negative subjects [2,7,11,19,21]. We found a clear
association of increased risk of renal disease with increas-
ing age (Figure 2g). The pooled relative risk of renal dis-
ease among PLHIV per 10 year increase in age was found
Table 2 Details of age categories
Study name Study type Period Disease Location study
size
Follow
up
Age (group
1) years
Age(group
2)years
RR 95%
Campbell, 2009 [10] cross-sectional 1998-2005 CKD BT, UK 3439 – > = 50
(Indinavir)
< 50 4.92 1.31, 18.4
Campbell, 2009 [10] cross-sectional 1998-2005 CKD UK 3439 – > = 50
(Tenofovir)
< 50 5.42 1.71, 16.8
Crane, 2007 [4] Cohort 2001-2006 Kidney
dysfunction
WA, USA 445 – 30-40 < 30 0.90 0.2, 3.2
Crane, 2007 [4] Cohort 2001-2006 Kidney
dysfunction
USA 445 – 40-50 < 30 2.10 0.6, 7.6
Crane, 2007 [4] Cohort 2001-2006 Kidney
dysfunction
USA 445 – > 50 < 40 4.40 1.1, 17.2
Franey, 2009 [13] Cohort 2004-2007 RI South
Africa
2189 – > 40 < 30 4.65 3.54, 6.10
Ganesan, 2010 [14] Cohort 1986-2008 CKD USA 4044 6.5 > = 35 < 35 2.6 1.7, 4.0
Lucas, 2007 [20] Cohort 1988-2004 CKD MD, USA 4509 4.6 30-49.9 < 30 1.50 0.7, 3.3
Lucas, 2007 [20] Cohort 1988-2004 CKD USA 4509 4.6 > = 50 < 50 2.00 0.8, 4.7
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to be 1.54 (1.16-2.05). The heterogeneity of this outcome
was estimated as I-squared = 87.6% (p < 0.001).
Other studies also link age to the relative risk of renal
disease among PLHIV but did not report age groups that
could be incorporated into comparable estimates for our
meta-analysis [4,10,13,14,20]. Campbell reported 81 CKD
stage 3 patients among 3439 PLHIV with GFR < 60 mL/
min for ≥ 3 months [10]. He estimated the relative risk
among patients aged ≥ 50 years initiating IDV/TDF to be
4.92 (1.31-18.4) and 5.42 (1.71-16.8), respectively, when
compared with patients aged less than 50 years [10].
Crane estimated the relative risk of 51 CKD stage 3
patients among 445 HIV-infected people who were aged
30-40 years, 40-50 years and over 50 years compared to
people less than 30 years to be 0.90 (0.2-3.2), 2.10 (0.6-7.6)
and 4.40 (1.4-6.8) respectively [4]. The other cohort stu-
dies [13,14,20] provided similar trends across age and CD4
counts. We found that the risk of renal disease among
HIV-infected people was positively correlated with age
(correlation, r = 0.71). The meta-analysis determined that
relative risk of renal disease in HIV-infected people by 10-
year increment in age was 1.54 (Figure 2h).
Meta-regression analysis
We performed univariate meta-regression to explore fac-
tors that might account for heterogeneity between the
relative risk of renal disease and the study characteristics.
Potential explanatory covariates considered were study
design, study period, duration of follow-up, diseases, study
location, study size, race/ethnicity and estimated glomeru-
lar filtration rate (eGFR) type. We found that geographic
location, type of disease and eGFR methods were signifi-
cantly associated with the relative risk of renal disease.
Sub-group outcomes
We performed three subgroup analyses based on the
results of meta-regression. We found that the adjusted
relative risk of renal disease associated with TDF was 2.01
(1.3-3.1) with a moderate amount of heterogeneity 53.7%
(p = 0.09)(which decreased from previously calculated het-
erogeneity of 78.4% (p = 0.001)) caused by geographic
location and eGFR. The type of disease reported causes
heterogeneity between studies in the analysis of the effect
of ART. Our resultant subgroup analysis by type of disease
(HIVAN) changed the estimates from a relative risk of
0.54 (0.29-0.99) with heterogeneity of 80.5% (p < 0.001) to
0.42 (0.18-0.97) with heterogeneity of 60.4% (p = 0.081).
We also found that type of disease (CKD) reported con-
tributed to heterogeneity of the estimates for every 10-year
increment in age. Our subgroup analysis by type of disease
changed the estimates from a relative risk of 1.54 (1.16-
2.05) with heterogeneity of 87.6% (p < 0.001) to 1.49 (1.29-
1.71) with null heterogeneity of 0.0% (p = 0.390). It is
noted that biopsy-proven HIV-associated nephropathy
(HIVAN) was not included in the classification of disease
in this subgroup analyses.
Table 3 Details of CD4 count categories
Study name Study
type
Period Diseases Location Study
size
Follow
up
CD4 (group 1)
cells/mm3
CD4(group 2)
cells/mm3
RR 95%
Deti, 2010 Cohort 2004-2008 CRF France 2613 3.4 < 200 > 500 4.04 2.3, 7.1
Deti, 2010 Cohort 2004-2008 CRF France 2613 3.4 200-500 > 500 1.33 0.81, 2.19
Franceschini,
2006
Cohort 2000-2002 ARF USA 705 3.0 < 200 > 200 4.70 2.5, 8.8
Ganesan,
2010
Cohort 1986-2008 CKD USA 4044 6.5 < = 200 > = 500 6.8 3.0, 15.5
Ganesan,
2010
Cohort 1986-2008 CKD USA 4044 6.5 201-349 > = 500 4.3 2.3, 8.1
Ganesan,
2010
Cohort 1986-2008 CKD USA 4044 6.5 350-499 > = 500 2.4 1.3, 4.6
Franey, 2009 Cohort 2004-2007 RI South
Africa
2189 – < 100 > 100 1.4 1.07, 1.82
Ibrahim, 2010 Cohort 1999-2008 ARF UK 2556 – 201-350 > 350 1.56 0.97, 2.48
Ibrahim, 2010 Cohort 1999-2008 ARF UK 2556 – 101-200 > 350 2.08 1.11, 3.91
Ibrahim, 2010 Cohort 1999-2008 ARF UK 2556 – 51-100 > 350 6.38 3.18, 12.78
Ibrahim, 2010 Cohort 1999-2008 ARF UK 2556 – 0-50 > 350 10.29 5.11, 20.98
Krawczyk,
2004
Cohort 1992-2002 CRF USA 6361 – < 200 200-349 4.3 2.1, 8.7
Roe, 2008 Cohort 1998-2005 ARF UK 2274 8.0 < 100 > 200 6.75 2.5, 18.3
Roe, 2008 Cohort 1998-2005 ARF UK 2274 8.0 100-199 > 200 3.02 0.99, 9.13
Szczech,
2002
Cohort 1994-1999 RF USA 2057 4.5 < = 200 > 200 3.57 1.72, 7.14
Wei, Cohort 1993-1997 HIVAN USA 44 5.1 < = 100 > = 100 2.73 0.82, 9.14
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Publication bias
We found no evidence of publication bias in our ana-
lyses. For example, among studies comparing relative
risk of renal disease between HIV-infected and unin-
fected people, there was no evidence of publication bias
by funnel plot symmetry, Egger’s p = 0.757. We found
similar estimates in other estimates with no significant
evidence of publication bias. However, other studies
may have been conducted to calculate the relative risk
of renal disease that were not published and identified
in our search methods.
Discussion
We conducted a systematic review and series of meta-ana-
lyses to calculate the pooled relative risk of renal disease
for PLHIV across available sources of evidence. Our analy-
sis suggests that PLHIV have increased risk of renal dis-
ease. Specifically, the relative risk of renal disease for
PLHIV was found to be 3.87 times greater than in HIV-
uninfected people. The relative risk of renal disease for
late-stage HIV infection (AIDS) was found to be 3.32
times more than that of PLHIV at earlier stages of infec-
tion. The relative risk of renal disease among PLHIV trea-
ted with ART was found to be decreased by 46%
compared to treatment-naïve PLHIV. This indicates that
ART could have a protective effect against renal disease in
PLHIV. We also found that the risk of renal disease for
HIV-infected people receiving TDF-based treatment was
found to be 56% greater than the risk for HIV-infected
people who are treated with non-TDF-based ART.
Our estimates are consistent with earlier reviews of spe-
cific associations with renal disease. A Multicentre AIDS
Cohort Study by Palella et al. [35] found the relative risk
of proteinuria with GFR decreased rate was 5.0 (p < 0.001)
among PLHIV without AIDS compared to HIV-uninfected
people and 2.18 (p = 0.02) among people with AIDS com-
pared to other PLHIV, respectively. A review of TDF con-
ducted by Cooper et al. found a non-significant effect of
TDF-based ART of 0.7% (0.02-1.2) [36]. We also found
that the duration of exposure to ART and age are impor-
tant contributors to the risk of acquiring renal disease:
specifically, each year of ART increased the relative risk by
an estimated 29% and each 10-year increment in age
increased the risk of renal disease by 54%.
One study identified in our search strategy, by Crane
et al. [4], did not have similar comparator groups with
other studies and thus could not be pooled in these esti-
mates. The study reported estimates in various age groups
and within ART groups. They found the risk of CKD
among people receiving tenofovir was greater if the
patients also received didanosine and amprenavir antiretro-
virals, were of greater age, and lower baseline weight [4].
The underlying reason for development of CKD in
HIV-infected patients is likely that HIV can cause direct
injury to the kidneys as manifested by HIVAN [37]. The
CKD can be developed by drug-induced nephrotoxicity
to prevent HIV-infection, dependent on exposure to anti-
retroviral drug regimen. TDF-induced regimens are more
likely to increase CKD than non-TDF-based regimen.
There are other mechanisms of developing CKD among
PLHIV as described in a recent study [37].
In our analyses we attempted to eliminate bias and con-
founding wherever possible. Individual studies controlled
for certain confounders between the treatment and control
groups but not all studies controlled for the same vari-
ables. Due to differences between study categorizations it
is possible that our analysis may have some bias due to
misclassification error. This may be particularly relevant
for comparisons between HIV-infected people receiving
ART versus treatment-naïve people because some of the
people with unknown treatment exposure could have
been classified as treatment-naïve. It is possible that there
are other important characteristics beyond the effects of
antiretroviral drugs that differ between populations of peo-
ple who are given and take ART and those who are not
treated. We were unable to conduct an analysis based on
duration of ART, which may be an important determining
factor. For individual studies in which there was some
uncertainty in definitions of populations in any arm we
conducted a sensitivity analysis by performing the meta-
analysis without the questioned study, but we found our
pooled estimates to be relatively robust. Our meta-analysis
ended up with relatively small numbers in each grouping
with reasonable amounts of heterogeneity. However, esti-
mates from our meta-analyses provided no significant evi-
dence of publication bias. Our effect measures were
relatively consistent among the trials. Also, abstracts did
not provide final, peer-reviewed, data and that the GFR
equations have not been validated in HIV populations.
Given these potential limitations, we believe our pooled
estimates are accurate indications of the relative risk of
CKD for HIV-infected people based on the available
empirical evidence. However, it is important to note the
importance of race/ethnicity, as it pertains to HIV-asso-
ciated kidney disease. We were unable to conduct sub-
analyses by race. However, a number of studies reported
that people of African descent among HIV-infected popu-
lation known to have high risk, as HIV-associated nephro-
pathy (HIVAN) occurs disproportionately among those of
African descent [9]. hepatitis C co-infection is also asso-
ciated with kidney disease which was not included in our
analysis [38].
Conclusion
Although the health and survival of PLHIV has improved
with effective antiretroviral therapies, HIV-infected peo-
ple are at substantially greater risk of developing other
co-morbidities, such as CKD, compared to uninfected
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people. This is a significant issue for populations of
PLHIV, particularly as they get older and become more
treatment experienced. Increasingly, HIV-positive popu-
lations will require long-term clinical management of
numerous conditions along with their HIV infection.
CKD is likely to be an important condition to be con-
fronted in the future in populations of PLHIV.
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